Cargando…
Oral Anticoagulant Therapy in Patients Receiving Haemodialysis: Is It Time to Abandon It?
Oral anticoagulant (OAC) therapy in haemodialysis patients causes a great deal of controversy. This is because a number of pro- and anticoagulant factors play an important role in end-stage renal failure due to the nature of the disease itself. In these conditions, the pharmacokinetic and pharmacody...
Autores principales: | Saracyn, Marek, Brodowska-Kania, Dorota, Niemczyk, Stanisław |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3863463/ https://www.ncbi.nlm.nih.gov/pubmed/24379737 http://dx.doi.org/10.1155/2013/170576 |
Ejemplares similares
-
First year survival of patients on maintenance dialysis treatment in Poland
por: Brodowska-Kania, Dorota, et al.
Publicado: (2015) -
Diabetic kidney disease: Are the reported associations with single-nucleotide polymorphisms disease-specific?
por: Saracyn, Marek, et al.
Publicado: (2021) -
SUN-274 Pituitary Macroadenoma Treated with Peptide Receptor Radionuclide Therapy in a Patient with Common Variable Immunodeficiency - Case Report
por: Brodowska-Kania, Dorota, et al.
Publicado: (2020) -
Assessment of the correlation of commonly used laboratory tests with clinical activity, renal involvement and treatment of systemic small-vessel vasculitis with the presence of ANCA antibodies
por: Mosakowska, Magdalena, et al.
Publicado: (2021) -
Vancomycin dosing in patients undergoing maintenance hemodialysis
por: Rymarz, Aleksandra, et al.
Publicado: (2014)